Back to Search Start Over

Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity

Source :
M2 Pharma. June 12, 2018
Publication Year :
2018

Abstract

M2 PHARMA-June 12, 2018-Saniona plans initiation of a phase 2a study with Tesomet for treatment of hypothalamic obesity (C)2018 M2 COMMUNICATIONS Biotechnology company Saniona AB (STO:SANION) announced on Monday that [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.542246607